The Key to Digital Compliance in the Pharmaceutical Industry – What is CFR 21 Part 11?
CFR 21 Part 11 is a regulation issued by the U.S. Food and Drug Administration (FDA) concerning the secure use of electronic records and electronic signatures.
Pharmaceutical, biotechnology, and medical device manufacturers are subject to FDA inspections, making compliance with these standards mandatory.
This regulation aims to ensure the accuracy, integrity, and traceability of data maintained in digital environments. It also defines the technical and administrative requirements for electronic signatures to be considered as legally valid as handwritten signatures.
When is CFR 21 Part 11 Required?
Your company must comply with CFR 21 Part 11 if it:
- Tracks production processes using electronic systems
- Conducts product-related quality controls through digital platforms
- Uses reporting, user management, and digital archiving systems
In these cases, CFR 21 Part 11 compliance is a legal obligation.
Key Requirements of CFR 21 Part 11
Validation:
Software systems must be proven to operate reliably, consistently, and accurately.
Record Copying and Retention:
Data stored in the system must be kept in proper formats and remain accessible when needed.
Access Control:
Only authorized personnel should have access to the system. Password policies and session management are mandatory.
Audit Trails:
Every action must be automatically recorded by the system with date and time stamps. These records must be non-editable.
Operational Controls:
Critical operations must follow a specific sequence, and the system must enforce this order.
Electronic Signatures:
User actions must be digitally signed and linked to their identity.
Why is CFR 21 Part 11 Compliance Important?
- To avoid penalties during FDA inspections
- To make production processes transparent, traceable, and auditable
- To ensure the legal validity of electronic records
- To prevent risks such as product recalls and quality violations
- To build trust in the digital infrastructure